MedPath

Digital Cognitive Behavior Therapy Program for Suicide Prevention

Not Applicable
Completed
Conditions
Suicidal Ideation
Depression
Anxiety
Interventions
Behavioral: Thrive
Registration Number
NCT03595254
Lead Sponsor
Montana State University
Brief Summary

This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling

Detailed Description

The efficacy of Thrive has been studied among patient and community populations and has shown to effectively reduce depression and anxiety symptoms among adults with moderate to severe depression symptoms at baseline.

This study will examine whether Thrive can also reduce suicidal thinking for persons exhibiting at least moderate depression symptoms. The first phase of the study will implement a randomized waitlist controlled trial. The second phase of the study will examine the effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and 16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
725
Inclusion Criteria
  • Montana resident
  • 18+ years old
  • Have regular access to broadband internet
  • PHQ-9 score greater than 4
Exclusion Criteria
  • No Montana residency
  • < 18 years old
  • No broadband internet access
  • PHQ-9 score less than 5

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Thrive InterventionThriveOnline cognitive behavior therapy program
Primary Outcome Measures
NameTimeMethod
Concise Health Risk Tracking2 Weeks

Suicidal Thinking; Score range 7 (better) - 35(worse)

Secondary Outcome Measures
NameTimeMethod
Work and Social Adjustment Scale1 Year

Functioning; Score range 0(better) - 40(worse)

Connor-Davidson Resilience Scale - Abbreviated Version1 month

Resilience; score range 0 (worse) - 40(better)

Patient Health Questionnaire-92 Weeks

Depression; Score range 0(better) - 27(worse)

Generalized Anxiety Disorder Scale-72 Weeks

Anxiety symptoms; Score range 0 (better) to 21 (worse)

Trial Locations

Locations (1)

Montana State University

🇺🇸

Bozeman, Montana, United States

© Copyright 2025. All Rights Reserved by MedPath